https://www.selleckchem.com/pr....oducts/bzatp-triethy
An amendment to this paper has been published and can be accessed via the original article. Office-based buprenorphine treatment of opioid use disorder (OUD) does not typically include in-person directly observed therapy (DOT), potentially leading to non-adherence. Video DOT technologies may safeguard against this issue and thus enhance likelihood of treatment success. We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAA study, a pilot randomized controlled
Gefällt mir
Kommentar
Teilen
